经过修改的Gingerenone A的衰老效应
Ruin Moaddel1, Chad Sanehira2, Gregory Keyes3
1Laboratory of Clinical Investigation, National Institute on Aging, Intramural Research Program, NIH, Baltimore, MD, USA. moaddelru@mail.nih.gov.
npj aging
|May 30, 2025
概括
银原A (GinA) 和其修改版 (modGinA) 通过清除衰老细胞,显示出老年治疗潜力. 这些化合物改善了老化表型,并增强了小鼠的代谢和线粒体功能.
科学领域:
- 生物化学 生化学
- 老年学是一门学科.
- 药理学 药理学是指药理学的学科.
背景情况:
- 衰老细胞随着年龄的增长而积累,导致与年龄相关的疾病和功能衰退.
- 消除衰老细胞的老化剂在改善衰老表型和慢性疾病健康方面表现有前途.
- 迄今为止,很少有老年治疗化合物 (老年化剂和老年化物) 已被确定.
研究的目的:
- 在老化小鼠模型中研究银仁A (GinA) 的老年治疗特性.
- 为了评估改性Gina化合物 (modGinA) 与eicosapentaenoic acid (EPA) 或docosahexaenoic acid (DHA) 的,以增强 senolytic和senomorphic效应.
主要方法:
- 给老化的小鼠模型注射了GinA和modGinA.
- 评估生化和组织学变化.
- 评估了新陈代谢和线粒体功能的改善.
主要成果:
- 无论是GinA还是modGinA都表现出老年治疗作用,包括抗炎症,老年化和老年化作用.
- 生物化学和组织学标记表明衰老的减少.
- 在接受治疗的小鼠中观察到代谢和线粒体功能的显著改善.
结论:
- 吉纳具有老年治疗性质.
- 修改后的Gina化合物 (modGinA) 增强了Gina的作用.
- 这些发现表明,GinA和modGinA在抗老化和相关疾病方面有潜在的治疗应用.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
278
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
278
Antianginal Drugs: Nitrates and β-Blockers
771
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
771
Dipeptidyl Peptidase 4 Inhibitors
271
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271
Combined Effects of Drugs: Synergism
4.9K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
4.9K
Oral Hypoglycemic Agents: Glinides
274
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
274


